To diagnose sensorineural hearing loss, Rinne and Weber tests can be used. In this type of hearing loss, air conduction will be louder than bone on Rinne test and Weber test will lateralise away from the affected ear. However, before making a diagnosis, it is important to correctly identify the symptoms. For example, sudden hearing loss accompanied by dizziness and pressure in the ear may indicate Meniere’s disease, which causes sensorineural hearing loss in the affected ear. If the symptoms suggest sensorineural hearing loss in the left ear, the results of the tests should show air conduction louder than bone on Rinne test and Weber test lateralising away from the left ear. If the results show different patterns, they may suggest conductive or mixed hearing loss in one or both ears.

Rinne’s and Weber’s Test for Differentiating Conductive and Sensorineural Deafness

Rinne’s and Weber’s tests are two diagnostic tools used to differentiate between conductive and sensorineural deafness. Rinne’s test involves placing a tuning fork over the mastoid process until the sound is no longer heard, then repositioning it just over the external acoustic meatus. A positive test indicates that air conduction (AC) is better than bone conduction (BC), while a negative test suggests conductive deafness if BC is greater than AC.

On the other hand, Weber’s test involves placing a tuning fork in the middle of the forehead equidistant from the patient’s ears and asking which side is loudest. In unilateral sensorineural deafness, sound is localized to the unaffected side, while in unilateral conductive deafness, sound is localized to the affected side.

To interpret the results of Rinne’s and Weber’s tests, a normal result indicates that AC is greater than BC bilaterally, and the sound is midline in Weber’s test. Conductive hearing loss is indicated by BC being greater than AC in the affected ear, while AC is greater than BC in the unaffected ear, and the sound lateralizes to the affected ear in Weber’s test. Sensorineural hearing loss is indicated by AC being greater than BC bilaterally, and the sound lateralizes to the unaffected ear in Weber’s test.

When there is no history of erythema migrans, ELISA is the primary test used to investigate suspected cases of Lyme disease.

Understanding Lyme Disease

Lyme disease is a bacterial infection caused by Borrelia burgdorferi and is transmitted through tick bites. The early symptoms of Lyme disease include erythema migrans, a characteristic bulls-eye rash that appears at the site of the tick bite. This rash is painless, slowly increases in size, and can be more than 5 cm in diameter. Other early symptoms include headache, lethargy, fever, and joint pain.

If erythema migrans is present, Lyme disease can be diagnosed clinically, and antibiotics should be started immediately. The first-line test for Lyme disease is an enzyme-linked immunosorbent assay (ELISA) to detect antibodies to Borrelia burgdorferi. If the ELISA is negative but Lyme disease is still suspected, it should be repeated 4-6 weeks later. If Lyme disease is suspected in patients who have had symptoms for 12 weeks or more, an immunoblot test should be done.

Tick bites can cause significant anxiety, but routine antibiotic treatment is not recommended by NICE. If the tick is still present, it should be removed using fine-tipped tweezers, and the area should be washed. In cases of suspected or confirmed Lyme disease, doxycycline is the preferred treatment for early disease, while ceftriaxone is used for disseminated disease. A Jarisch-Herxheimer reaction may occur after initiating therapy, which can cause fever, rash, and tachycardia.

In summary, Lyme disease is a bacterial infection transmitted through tick bites. Early symptoms include erythema migrans, headache, lethargy, fever, and joint pain. Diagnosis is made through clinical presentation and ELISA testing, and treatment involves antibiotics. Tick bites do not require routine antibiotic treatment, and ticks should be removed using fine-tipped tweezers.

If a patient has poorly controlled hypertension despite being on an ACE inhibitor, CCB, and thiazide diuretic, adding an alpha- or beta-blocker is recommended by NICE if their potassium levels are above 4.5mmol/l. It is important to assess the patient for postural hypotension and discuss adherence with them. Seeking specialist advice is also advised. Fludrocortisone is not appropriate for treating hypertension and may increase blood pressure. Spironolactone would be the next step if potassium levels were below 4.5mmol/l. Indapamide cannot be increased any further if the patient is already on the maximum dose. It is important to treat hypertension promptly, especially if it has been confirmed through ABPM on multiple occasions.

NICE Guidelines for Managing Hypertension

Hypertension, or high blood pressure, is a common condition that can lead to serious health problems if left untreated. The National Institute for Health and Care Excellence (NICE) has published updated guidelines for the management of hypertension in 2019. Some of the key changes include lowering the threshold for treating stage 1 hypertension in patients under 80 years old, allowing the use of angiotensin receptor blockers instead of ACE inhibitors, and recommending the use of a calcium channel blocker or thiazide-like diuretic in addition to an ACE inhibitor or angiotensin receptor blocker.

The guidelines also provide a flow chart for the diagnosis and management of hypertension. Lifestyle advice, such as reducing salt intake, caffeine intake, and alcohol consumption, as well as exercising more and losing weight, should not be forgotten and is frequently tested in exams. Treatment options depend on the patient’s age, ethnicity, and other factors, and may involve a combination of drugs.

NICE recommends treating stage 1 hypertension in patients under 80 years old if they have target organ damage, established cardiovascular disease, renal disease, diabetes, or a 10-year cardiovascular risk equivalent to 10% or greater. For patients with stage 2 hypertension, drug treatment should be offered regardless of age. The guidelines also provide step-by-step treatment options, including adding a third or fourth drug if necessary.

New drugs, such as direct renin inhibitors like Aliskiren, may have a role in patients who are intolerant of more established antihypertensive drugs. However, trials have only investigated the fall in blood pressure and no mortality data is available yet. Patients who fail to respond to step 4 measures should be referred to a specialist. The guidelines also provide blood pressure targets for different age groups.

It may take up to 6 months of Finasteride treatment for results to become noticeable in BPH.

Benign prostatic hyperplasia (BPH) is a common condition that affects older men, with around 50% of 50-year-old men showing evidence of BPH and 30% experiencing symptoms. The risk of BPH increases with age, with around 80% of 80-year-old men having evidence of the condition. BPH typically presents with lower urinary tract symptoms (LUTS), which can be categorised into voiding symptoms (obstructive) and storage symptoms (irritative). Complications of BPH can include urinary tract infections, retention, and obstructive uropathy.

Assessment of BPH may involve dipstick urine tests, U&Es, and PSA tests. A urinary frequency-volume chart and the International Prostate Symptom Score (IPSS) can also be used to assess the severity of LUTS and their impact on quality of life. Management options for BPH include watchful waiting, alpha-1 antagonists, 5 alpha-reductase inhibitors, combination therapy, and surgery. Alpha-1 antagonists are considered first-line treatment for moderate-to-severe voiding symptoms, while 5 alpha-reductase inhibitors may be indicated for patients with significantly enlarged prostates and a high risk of progression. Combination therapy and antimuscarinic drugs may also be used in certain cases. Surgery, such as transurethral resection of the prostate (TURP), may be necessary in severe cases.

The most significant risk factor for cervical cancer is infection with the human papillomavirus (HPV), particularly types 16, 18, and 33. Among the approximately 15 types of HPV that are considered high-risk for cervical cancer, HPV 16 and 18 are responsible for about 70% of cases. HPV 6 and 11, on the other hand, are associated with the formation of genital warts.

Understanding Cervical Cancer: Risk Factors and Mechanism of HPV

Cervical cancer is a type of cancer that affects the cervix, which is the lower part of the uterus. It is most commonly diagnosed in women under the age of 45, with the highest incidence rates occurring in those aged 25-29. The cancer can be divided into two types: squamous cell cancer and adenocarcinoma. Symptoms may include abnormal vaginal bleeding, postcoital bleeding, intermenstrual bleeding, or postmenopausal bleeding, as well as vaginal discharge.

The most important factor in the development of cervical cancer is the human papillomavirus (HPV), particularly serotypes 16, 18, and 33. Other risk factors include smoking, human immunodeficiency virus, early first intercourse, many sexual partners, high parity, and lower socioeconomic status. While the association between combined oral contraceptive pill use and cervical cancer is sometimes debated, a large study published in the Lancet confirmed the link.

The mechanism by which HPV causes cervical cancer involves the production of oncogenes E6 and E7 by HPV 16 and 18, respectively. E6 inhibits the p53 tumour suppressor gene, while E7 inhibits the RB suppressor gene. Understanding the risk factors and mechanism of HPV in the development of cervical cancer is crucial for prevention and early detection. Regular cervical cancer screening is recommended for all women.

Drug Management for Chronic Heart Failure: NICE Guidelines

Chronic heart failure is a serious condition that requires proper management to improve patient outcomes. In 2018, the National Institute for Health and Care Excellence (NICE) updated their guidelines on drug management for chronic heart failure. The guidelines recommend first-line therapy with both an ACE-inhibitor and a beta-blocker, with clinical judgement used to determine which one to start first. Second-line therapy involves the use of aldosterone antagonists, which should be monitored for hyperkalaemia. SGLT-2 inhibitors are also increasingly being used to manage heart failure with a reduced ejection fraction. Third-line therapy should be initiated by a specialist and may include ivabradine, sacubitril-valsartan, hydralazine in combination with nitrate, digoxin, or cardiac resynchronisation therapy. Other treatments such as annual influenza and one-off pneumococcal vaccines are also recommended.

Overall, the NICE guidelines provide a comprehensive approach to drug management for chronic heart failure. It is important to note that loop diuretics have not been shown to reduce mortality in the long-term, and that ACE-inhibitors and beta-blockers have no effect on mortality in heart failure with preserved ejection fraction. Healthcare professionals should carefully consider the patient’s individual needs and circumstances when determining the appropriate drug therapy for chronic heart failure.

Lynch syndrome is a genetic condition that increases the risk of developing colorectal cancer by over 80%. It also raises the risk of other cancers such as endometrial, stomach, breast, ovarian, small bowel, pancreatic, prostate, urinary tract, kidney, and liver cancer. Genetic testing is recommended for anyone diagnosed with colorectal cancer, regardless of age.

Breast cancer (BRCA) mutations are inherited in an autosomal dominant pattern and significantly increase the risk of developing breast, ovarian, prostate, and pancreatic cancer. These cancers tend to occur at a younger age than in the general population. While there is a possible link to colorectal pathology, other genetic syndromes should be considered first when looking for a genetic cause of cancer.

Cowden syndrome is a rare genetic condition characterized by benign growths called hamartomas on various parts of the body. It increases the risk of developing breast, thyroid, or endometrial cancer but has no association with colorectal cancer.

Familial adenomatous polyposis is an autosomal dominant condition that causes widespread colorectal adenomas, with polyps usually developing in late childhood. This greatly increases the risk of colorectal cancer, and prophylactic colectomy is often performed. Screening is recommended for those with an affected first-degree relative or multiple polyps detected on colonoscopy.

Von Hippel-Landau (VHL) syndrome is an autosomal dominant condition that causes multiple benign tumors and cysts in various parts of the body, including the brain, spinal cord, eyes, adrenals, kidneys, and pancreas. It increases the risk of renal and pancreatic cancer but has no association with colorectal cancer.

The Dix-Hallpike test involves quickly moving the patient to a supine position with their neck extended to determine if they experience symptoms of benign paroxysmal positional vertigo. A positive result can confirm the diagnosis. Based on the symptoms, it is likely that this patient has this condition.

Understanding Benign Paroxysmal Positional Vertigo

Benign paroxysmal positional vertigo (BPPV) is a common condition that causes sudden dizziness and vertigo triggered by changes in head position. It typically affects individuals over the age of 55 and is less common in younger patients. Symptoms include vertigo triggered by movements such as rolling over in bed or looking upwards, and may be accompanied by nausea. Each episode usually lasts between 10-20 seconds and can be diagnosed through a positive Dix-Hallpike manoeuvre, which involves the patient experiencing vertigo and rotatory nystagmus.

Fortunately, BPPV has a good prognosis and often resolves on its own within a few weeks to months. Treatment options include the Epley manoeuvre, which is successful in around 80% of cases, and vestibular rehabilitation exercises such as the Brandt-Daroff exercises. While medication such as Betahistine may be prescribed, it tends to have limited value. However, it is important to note that around half of people with BPPV will experience a recurrence of symptoms 3-5 years after their initial diagnosis.

Overall, understanding BPPV and its symptoms can help individuals seek appropriate treatment and manage their condition effectively.

After an ACS, it is recommended that all patients receive a combination of medications to reduce the risk of future coronary events. This includes dual antiplatelet therapy (aspirin plus a second antiplatelet agent), an ACE inhibitor, a beta-blocker, and a statin. The correct option for this patient would be a combination of atorvastatin, ramipril, clopidogrel, aspirin, and carvedilol. Atorvastatin is given to reduce cholesterol and prevent further coronary plaque formation, while ramipril is used to prevent cardiac remodeling and preserve left ventricular systolic function. Dual antiplatelet therapy with aspirin and clopidogrel is given to reduce the risk of thrombosis formation after PCI. Finally, beta-blockers such as carvedilol are used to improve prognosis, reduce the risk of arrhythmias, and have cardioprotective effects.

Myocardial infarction (MI) is a serious condition that requires proper management to prevent further complications. In 2013, NICE released guidelines on the secondary prevention of MI. One of the key recommendations is the use of four drugs: dual antiplatelet therapy (aspirin plus a second antiplatelet agent), ACE inhibitor, beta-blocker, and statin. Patients are also advised to adopt a Mediterranean-style diet and engage in regular exercise. Sexual activity may resume four weeks after an uncomplicated MI, and PDE5 inhibitors may be used six months after the event.

Most patients with acute coronary syndrome are now given dual antiplatelet therapy, with ticagrelor and prasugrel being the preferred options. The treatment period for these drugs is 12 months, after which they should be stopped. However, this period may be adjusted for patients at high risk of bleeding or further ischaemic events. Additionally, patients with heart failure and left ventricular systolic dysfunction should be treated with an aldosterone antagonist within 3-14 days of the MI, preferably after ACE inhibitor therapy.

Overall, the NICE guidelines provide a comprehensive approach to the secondary prevention of MI. By following these recommendations, patients can reduce their risk of further complications and improve their overall health outcomes.

Common Heart Murmurs and their Characteristics

Heart murmurs are abnormal sounds heard during a heartbeat and can indicate underlying heart conditions. Here are some common heart murmurs and their characteristics:

1. Ventricular Septal Defect (VSD): This has a pansystolic murmur, heard loudest at the lower left sternal edge and causing biventricular hypertrophy due to increased strain on both the right and left ventricles.

2. Mitral Regurgitation: This has a pansystolic murmur which is heard loudest at the apex and radiates to the axilla; it is louder on expiration. The ECG can show left ventricular and left atrial enlargement.

3. Aortic Stenosis: This causes a crescendo-decrescendo murmur, heard loudest in the aortic area and radiating to the carotids. It (and all other left-sided murmurs) is louder on expiration.

4. Hypertrophic Cardiomyopathy (HCM): HCM has an early peaking systolic murmur which is worse on Valsalva and reduced on squatting. It is also associated with a jerky pulse. The ECG would show left ventricular hypertrophy.

5. Tricuspid Regurgitation: This has a pansystolic murmur and a brief rumbling diastolic murmur; these are louder on inspiration. The ECG may show right ventricular enlargement.

It is important to note that right-sided murmurs increase with inspiration (e.g. tricuspid regurgitation or TR), whereas left-sided murmurs show no change. The clue to diagnosis is in the ECG finding. Aortic stenosis and mitral regurgitation produce left ventricular hypertrophy; TR produces right ventricular hypertrophy and a VSD produces biventricular hypertrophy.

Proliferative retinopathy is characterized by the presence of retinal neovascularization.

Understanding Diabetic Retinopathy

Diabetic retinopathy is a leading cause of blindness among adults aged 35-65 years old. The condition is caused by hyperglycemia, which leads to abnormal metabolism in the retinal vessel walls and damage to endothelial cells and pericytes. This damage causes increased vascular permeability, resulting in exudates seen on fundoscopy. Pericyte dysfunction predisposes to the formation of microaneurysms, while neovascularization is caused by the production of growth factors in response to retinal ischemia.

Patients with diabetic retinopathy are classified into those with non-proliferative diabetic retinopathy (NPDR), proliferative retinopathy (PDR), and maculopathy. NPDR is further classified into mild, moderate, and severe, depending on the presence of microaneurysms, blot hemorrhages, hard exudates, cotton wool spots, venous beading/looping, and intraretinal microvascular abnormalities. PDR is characterized by retinal neovascularization, which may lead to vitreous hemorrhage, and fibrous tissue forming anterior to the retinal disc. Maculopathy is based on location rather than severity and is more common in Type II DM.

Management of diabetic retinopathy involves optimizing glycaemic control, blood pressure, and hyperlipidemia, as well as regular review by ophthalmology. Treatment options include intravitreal vascular endothelial growth factor (VEGF) inhibitors for maculopathy, regular observation for non-proliferative retinopathy, and panretinal laser photocoagulation and intravitreal VEGF inhibitors for proliferative retinopathy. Vitreoretinal surgery may be necessary in cases of severe or vitreous hemorrhage.

Patients with HIV infection commonly experience diarrhoea as a result of Cryptosporidium, while respiratory infection may be caused by Histoplasmosis.

Diarrhoea in HIV Patients: Causes and Management

Diarrhoea is a common symptom experienced by patients with HIV. It can be caused by the virus itself, known as HIV enteritis, or by opportunistic infections. The most common infective cause of diarrhoea in HIV patients is Cryptosporidium, an intracellular protozoa with an incubation period of 7 days. Symptoms can range from mild to severe diarrhoea, and diagnosis is made through a modified Ziehl-Neelsen stain of the stool. Unfortunately, treatment is difficult, and supportive therapy is the mainstay of management.

Other possible causes of diarrhoea in HIV patients include Cytomegalovirus, Mycobacterium avium intracellulare, and Giardia. Mycobacterium avium intracellulare is an atypical mycobacteria that is typically seen when the CD4 count is below 50. Symptoms include fever, sweats, abdominal pain, and diarrhoea, and diagnosis is made through blood cultures and bone marrow examination. Management involves the use of rifabutin, ethambutol, and clarithromycin.

In summary, diarrhoea is a common symptom experienced by HIV patients, and it can be caused by a variety of opportunistic infections. While treatment can be difficult, supportive therapy can help manage symptoms. It is important for healthcare providers to be aware of the potential causes of diarrhoea in HIV patients and to work with their patients to develop an appropriate management plan.

Differential Diagnosis of Endocrine Disorders: Symptoms and Treatment Options

Hypothyroidism, adrenal insufficiency, Cushing syndrome, primary hypoparathyroidism, and secondary hypoparathyroidism are all endocrine disorders that can present with various symptoms. Hypothyroidism may cause cerebellar ataxia, myxoedema, and congestive cardiac failure, and is treated with replacement of thyroid hormone. Adrenal insufficiency may cause tiredness, weakness, and postural hypotension, among other symptoms. Cushing syndrome may present with central obesity, skin and muscle atrophy, and osteoporosis. Primary hypoparathyroidism may cause hypocalcaemia symptoms, while secondary hypoparathyroidism may also present with hypocalcaemia symptoms. Treatment options vary depending on the specific disorder.

Azithromycin or clarithromycin are recommended as first-line antibiotics for non-pregnant adults with whooping cough if the cough onset is within 21 days. Erythromycin can be used for pregnant adults. Co-amoxiclav and doxycycline are not recommended, and co-trimoxazole can be used off-label if macrolides are contraindicated or not tolerated. Antibiotics are preferred over supportive treatment within 21 days of presentation.

Whooping Cough: Causes, Symptoms, Diagnosis, and Management

Whooping cough, also known as pertussis, is a contagious disease caused by the bacterium Bordetella pertussis. It is commonly found in children, with around 1,000 cases reported annually in the UK. The disease is characterized by a persistent cough that can last up to 100 days, hence the name cough of 100 days.

Infants are particularly vulnerable to whooping cough, which is why routine immunization is recommended at 2, 3, 4 months, and 3-5 years. However, neither infection nor immunization provides lifelong protection, and adolescents and adults may still develop the disease.

Whooping cough has three phases: the catarrhal phase, the paroxysmal phase, and the convalescent phase. The catarrhal phase lasts around 1-2 weeks and presents symptoms similar to a viral upper respiratory tract infection. The paroxysmal phase is characterized by a severe cough that worsens at night and after feeding, and may be accompanied by vomiting and central cyanosis. The convalescent phase is when the cough subsides over weeks to months.

To diagnose whooping cough, a person must have an acute cough that has lasted for 14 days or more without another apparent cause, and have one or more of the following features: paroxysmal cough, inspiratory whoop, post-tussive vomiting, or undiagnosed apnoeic attacks in young infants. A nasal swab culture for Bordetella pertussis is used to confirm the diagnosis, although PCR and serology are increasingly used.

Infants under 6 months with suspected pertussis should be admitted, and in the UK, pertussis is a notifiable disease. An oral macrolide, such as clarithromycin, azithromycin, or erythromycin, is indicated if the onset of the cough is within the previous 21 days to eradicate the organism and reduce the spread. Household contacts should be offered antibiotic prophylaxis, although antibiotic therapy has not been shown to alter the course of the illness. School exclusion is recommended for 48 hours after commencing antibiotics or 21 days from onset of symptoms if no antibiotics are given.

Complications of whooping cough include subconjunctival haemorrhage, pneumonia, bronchiectasis, and

DIC can cause haemorrhagic or thrombotic complications in cases of acute lymphoblastic leukaemia.

While a petechial rash can be a result of trauma, it is unlikely to be the case with this child given the other significant symptoms present. The non-blanching rash may initially suggest meningococcal disease, but the absence of fever and a clear source of infection makes this less likely. Additionally, the lesions associated with Henoch-Schonlein purpura typically appear on specific areas of the body and are accompanied by other symptoms such as haematuria or joint pain, which are not present in this case.

Acute lymphoblastic leukaemia (ALL) is a type of cancer that commonly affects children and accounts for 80% of childhood leukaemias. It is most prevalent in children between the ages of 2-5 years, with boys being slightly more affected than girls. Symptoms of ALL can be divided into those caused by bone marrow failure, such as anaemia, neutropaenia, and thrombocytopenia, and other features like bone pain, splenomegaly, and hepatomegaly. Fever is also present in up to 50% of new cases, which may indicate an infection or a constitutional symptom. Testicular swelling may also occur.

There are three types of ALL: common ALL, T-cell ALL, and B-cell ALL. Common ALL is the most common type, accounting for 75% of cases, and is characterized by the presence of CD10 and a pre-B phenotype. Poor prognostic factors for ALL include age less than 2 years or greater than 10 years, a white blood cell count greater than 20 * 109/l at diagnosis, T or B cell surface markers, non-Caucasian ethnicity, and male sex.

If general advice has not been effective, an enuresis alarm is typically the initial treatment for nocturnal enuresis. It is not advisable to limit fluid intake. According to Clinical Knowledge Summaries, children should consume approximately eight drinks per day, evenly distributed throughout the day, with the last one consumed approximately one hour before bedtime.

Nocturnal enuresis, or bedwetting, is when a child involuntarily urinates during the night. Most children achieve continence by the age of 3 or 4, so enuresis is defined as the involuntary discharge of urine in a child aged 5 or older without any underlying medical conditions. Enuresis can be primary, meaning the child has never achieved continence, or secondary, meaning the child has been dry for at least 6 months before.

When managing bedwetting, it’s important to look for any underlying causes or triggers, such as constipation, diabetes mellitus, or recent onset UTIs. General advice includes monitoring fluid intake and encouraging regular toileting patterns, such as emptying the bladder before sleep. Reward systems, like star charts, can also be helpful, but should be given for agreed behavior rather than dry nights.

The first-line treatment for bedwetting is an enuresis alarm, which has a high success rate. These alarms have sensor pads that detect wetness and wake the child up to use the toilet. If short-term control is needed, such as for sleepovers, or if the alarm is ineffective or not acceptable to the family, desmopressin may be prescribed. Overall, managing bedwetting involves identifying any underlying causes and implementing strategies to promote continence.

Breast cancer management varies depending on the stage of the cancer, type of tumor, and patient’s medical history. Treatment options may include surgery, radiotherapy, hormone therapy, biological therapy, and chemotherapy. Surgery is typically the first option for most patients, except for elderly patients with metastatic disease who may benefit more from hormonal therapy. Prior to surgery, an axillary ultrasound is recommended for patients without palpable axillary lymphadenopathy, while those with clinically palpable lymphadenopathy require axillary node clearance. The type of surgery offered depends on various factors, such as tumor size, location, and type. Breast reconstruction is also an option for patients who have undergone a mastectomy.

Radiotherapy is recommended after a wide-local excision to reduce the risk of recurrence, while mastectomy patients may receive radiotherapy for T3-T4 tumors or those with four or more positive axillary nodes. Hormonal therapy is offered if tumors are positive for hormone receptors, with tamoxifen being used in pre- and peri-menopausal women and aromatase inhibitors like anastrozole in post-menopausal women. Tamoxifen may increase the risk of endometrial cancer, venous thromboembolism, and menopausal symptoms. Biological therapy, such as trastuzumab, is used for HER2-positive tumors but cannot be used in patients with a history of heart disorders. Chemotherapy may be used before or after surgery, depending on the stage of the tumor and the presence of axillary node disease. FEC-D is commonly used in the latter case.

The egg ladder can be used to reintroduce egg in children with non-IgE mediated allergy, starting with baked egg in biscuits. Chlorpheniramine and adrenaline pen are not appropriate choices.

Identifying and Managing Food Allergies in Children and Young People

Food allergies in children and young people can be categorized into IgE-mediated and non-IgE-mediated allergies. It is important to note that food intolerance is not caused by immune system dysfunction and is not covered by the 2011 NICE guidelines. Symptoms of IgE-mediated allergies include skin reactions such as pruritus, erythema, urticaria, and angioedema, gastrointestinal symptoms like nausea, colicky abdominal pain, vomiting, and diarrhea, and respiratory symptoms such as nasal itching, sneezing, rhinorrhea, congestion, cough, chest tightness, wheezing, and shortness of breath. Non-IgE-mediated allergies may present with symptoms like gastro-oesophageal reflux disease, loose or frequent stools, blood and/or mucus in stools, abdominal pain, infantile colic, food refusal or aversion, constipation, perianal redness, pallor and tiredness, and faltering growth.

If the history suggests an IgE-mediated allergy, skin prick tests or blood tests for specific IgE antibodies to the suspected foods and likely co-allergens should be offered. On the other hand, if the history suggests a non-IgE-mediated allergy, the suspected allergen should be eliminated for 2-6 weeks and then reintroduced. It is recommended to consult a dietitian with appropriate competencies about nutritional adequacies, timings, and follow-up. By identifying and managing food allergies in children and young people, we can prevent severe allergic reactions and improve their quality of life.

Oral antiretroviral therapy for 4 weeks is used as post-exposure prophylaxis for HIV.

Post-exposure prophylaxis (PEP) is a preventive treatment given to individuals who have been exposed to an infectious disease. The type of PEP given depends on the specific disease and the circumstances of the exposure.

For hepatitis A, either human normal immunoglobulin (HNIG) or the hepatitis A vaccine may be used.

For hepatitis B, if the source is HBsAg positive, a booster dose of the HBV vaccine should be given to known responders. Non-responders require hepatitis B immune globulin (HBIG) and a booster vaccine. If the source is unknown, known responders may receive a booster dose of the HBV vaccine, while known non-responders require HBIG and a vaccine. Those in the process of being vaccinated should have an accelerated course of the HBV vaccine.

For hepatitis C, monthly PCR is recommended, and if seroconversion occurs, interferon +/- ribavirin may be given.

For HIV, the risk of transmission depends on the incident and the current viral load of the patient. Low-risk incidents such as human bites generally do not require PEP. However, for high-risk incidents, a combination of oral antiretrovirals should be given as soon as possible for four weeks. For varicella zoster, VZIG is recommended for IgG negative pregnant women or immunosuppressed individuals. It is important to note that the risk of transmission varies depending on the virus, with hepatitis B having a higher risk than hepatitis C and HIV.

To calculate alcohol units, multiply the volume in milliliters by the alcohol by volume (ABV) and divide by 1,000.

Alcohol consumption guidelines were revised in 2016 by the Chief Medical Officer, based on recommendations from an expert group report. The most significant change was a reduction in the recommended maximum number of units of alcohol for men from 21 to 14, aligning with the guidelines for women. The government now advises that both men and women should not exceed 14 units of alcohol per week, and if they do, it is best to spread it evenly over three or more days. Pregnant women are advised not to drink alcohol at all, as it can cause long-term harm to the baby. One unit of alcohol is equivalent to 10 mL of pure ethanol, and the strength of a drink is determined by its alcohol by volume (ABV). Examples of one unit of alcohol include a 25ml single measure of spirits with an ABV of 40%, a third of a pint of beer with an ABV of 5-6%, and half a 175ml standard glass of red wine with an ABV of 12%. To calculate the number of units in a drink, multiply the number of millilitres by the ABV and divide by 1,000.